These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1689891)

  • 21. Reversal of accelerated renal allograft rejection with FK 506.
    Woodle ES; Newell KA; Haas M; Bartosh S; Josephson MA; Millis JM; Bruce DS; Piper JB; Aronson AJ; Thistlethwaite JR
    Clin Transplant; 1997 Aug; 11(4):251-4. PubMed ID: 9267710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
    Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
    Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
    [No Abstract]   [Full Text] [Related]  

  • 23. Importance of allograft biopsy in renal transplant recipients: correlation between clinical and histological diagnosis.
    Al-Awwa IA; Hariharan S; First MR
    Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S15-8. PubMed ID: 9631859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notes on FK 506.
    Starzl TE; Fung J; Todo S; Tzakis A
    Transplant Proc; 1991 Aug; 23(4):2178-9. PubMed ID: 1714647
    [No Abstract]   [Full Text] [Related]  

  • 25. FK 506 dose in transplantation: from theory to practice.
    Faivre L; Saoudi S; Astier A; Hamadas C; Conort O; Boivin H; Sabatier B; Taburet A; Lecointre K; Bellanger A; Radideau E; Thuillier A
    Transplant Proc; 2001 Jun; 33(4):2594-7. PubMed ID: 11406256
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
    Rubik J; Debray D; Kelly D; Iserin F; Webb NJA; Czubkowski P; Vondrak K; Sellier-Leclerc AL; Rivet C; Riva S; Tönshoff B; D'Antiga L; Marks SD; Reding R; Kazeem G; Undre N
    Transpl Int; 2019 Nov; 32(11):1182-1193. PubMed ID: 31325368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts.
    Lautenschlager I; Höckerstedt K; Mäkisalo H; Orko R; Taskinen E
    Transplant Proc; 1991 Aug; 23(4):2233-5. PubMed ID: 1714650
    [No Abstract]   [Full Text] [Related]  

  • 28. Interspecies comparison of the immunosuppressive efficacy and safety of FK 506.
    Thomson AW
    Transplant Proc; 1990 Feb; 22(1):100-5. PubMed ID: 1689883
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of FK 506 in pediatric patients.
    Tzakis AG; Fung JJ; Todo S; Reyes J; Green M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):924-7. PubMed ID: 1703353
    [No Abstract]   [Full Text] [Related]  

  • 30. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of T-cell receptor-V region determinants on infiltrating T cells in rejecting and nonrejecting human kidney, liver, and heart allografts.
    Ibrahim S; Dawson DV; Elmohsen MA; Elsamannoudy FA; Sanfilippo F
    Transplant Proc; 1993 Feb; 25(1 Pt 1):80-3. PubMed ID: 8438488
    [No Abstract]   [Full Text] [Related]  

  • 32. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy.
    Ben-Ari Z; Mor E; Shaharabani E; Bar-Nathan N; Shapira Z; Tur-Kaspa R
    Transplant Proc; 2000 Jun; 32(4):709-10. PubMed ID: 10856553
    [No Abstract]   [Full Text] [Related]  

  • 33. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients: a viewpoint by Helio Tedesco Silva Jr.
    Silva HT
    Drugs; 2007; 67(13):1944-5. PubMed ID: 17722963
    [No Abstract]   [Full Text] [Related]  

  • 34. The impact of Cyclosporin A on transplantation.
    Morris PJ
    Adv Surg; 1984; 17():99-127. PubMed ID: 6367397
    [No Abstract]   [Full Text] [Related]  

  • 35. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression.
    Sakai K; Miyagi Y; Hasegawa T; Itabashi Y; Muramatsu M; Sugiyama K; Kawamura T; Arai K; Aikawa A; Ohara T; Mizuiri S; Hasegawa A
    Transplant Proc; 2005 May; 37(4):1757-9. PubMed ID: 15919455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of endocardial lymphoid infiltrates (Quilty lesions) in nonheart transplant recipients treated with cyclosporine.
    Barone JH; Fishbein MC; Czer LS; Blanche C; Trento A; Luthringer DJ
    J Heart Lung Transplant; 1997 Jun; 16(6):600-3. PubMed ID: 9229289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil rescue therapy in liver transplant recipients.
    Gavlik A; Goldberg MG; Tsaroucha A; Webb MG; Khan RT; Weppler D; Nery JR; Khan MF; Zucker K; Viciana AL; Miller JA; Tzakis AG
    Transplant Proc; 1997; 29(1-2):549-52. PubMed ID: 9123124
    [No Abstract]   [Full Text] [Related]  

  • 38. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A.
    Kanzler S; Lohse AW; Schirmacher P; Hermann E; Otto G; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1996 Feb; 34(2):128-31. PubMed ID: 8659188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of Cyclosporin A immunosuppression in organ grafting.
    White DJ; Calne RY
    Immunol Rev; 1982; 65():115-31. PubMed ID: 6214494
    [No Abstract]   [Full Text] [Related]  

  • 40. FK 506--an investigational immunosuppressant.
    Med Lett Drugs Ther; 1991 Oct; 33(854):94. PubMed ID: 1716722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.